IGM Biosciences, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 30 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-10-02: Reporting owner Harler Mary Beth; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-07-25: Reporting owner Hambleton Julie; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2024-07-19: Reporting owner Takimoto Chris H; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2024-07-19: Reporting owner Tahir Misbah; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-10-02 | Harler Mary Beth Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +370,000 370,000 owned after | $14.40 exercise price | 2024-10-04 | |
| 2024-07-25 | Hambleton Julie Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,132 0 owned after | $1.39 exercise price | 2024-07-29 | |
| 2024-07-19 | Takimoto Chris H Officer (CHIEF MEDICAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −150,000 0 owned after | $68.01 exercise price | 2024-07-23 | |
| 2024-07-19 | Tahir Misbah Officer (CHIEF FINANCIAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −55,000 0 owned after | $40.27 exercise price | 2024-07-23 | |
| 2024-07-19 | Tahir Misbah Officer (CHIEF FINANCIAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,000 0 owned after | $91.50 exercise price | 2024-07-23 | |
| 2024-07-19 | Keyt Bruce Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −75,000 0 owned after | $40.27 exercise price | 2024-07-23 | |
| 2024-07-19 | Keyt Bruce Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $91.50 exercise price | 2024-07-23 | |
| 2024-07-19 | Harler Mary Beth Officer (Head, Research & Autoimmunity) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −200,000 0 owned after | $61.45 exercise price | 2024-07-23 | |
| 2024-07-19 | Decker Lisa Lynn Officer (CHIEF BUSINESS OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −60,000 0 owned after | $86.24 exercise price | 2024-07-23 | |
| 2024-04-23 holding as of filing | Harler Mary Beth Officer (Head, Research & Autoimmunity) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $61.45 exercise price | 2024-04-23 | ||
| 2024-04-23 holding as of filing | Harler Mary Beth Officer (Head, Research & Autoimmunity) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.11 exercise price | 2024-04-23 | ||
| 2024-04-23 holding as of filing | Harler Mary Beth Officer (Head, Research & Autoimmunity) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $12.86 exercise price | 2024-04-23 | ||
| 2024-04-23 holding as of filing | Harler Mary Beth Officer (Head, Research & Autoimmunity) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $9.95 exercise price | 2024-04-23 | ||
| 2024-03-12 | Redmile Group, LLC | Green Jeremy Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See Footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Lee Michael Stewart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Weber Steven Officer (PRINCIPAL ACCOUNTING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Takimoto Chris H Officer (CHIEF MEDICAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,500 92,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Tahir Misbah Officer (CHIEF FINANCIAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,500 92,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Schwarzer Fred Director, Officer (CEO AND PRESIDENT) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +245,500 245,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Keyt Bruce Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,500 92,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Decker Lisa Lynn Officer (CHIEF BUSINESS OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,500 57,500 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Topsoe Jakob Haldor Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Topsoe Christina Teng Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Thompson Elizabeth H.Z. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Strohl William Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | Hambleton Julie Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | BEHRENS M KATHLEEN Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | BAKER JULIAN | BAKER FELIX | Baker Brothers Life Sciences LP | Baker Bros. Advisors (GP) LLC | 667, L.P. | BAKER BROS. ADVISORS LP Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Non- Qualified Stock Option (right to buy)uy) Derivative · Indirect · See Footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-12 | BAKER JULIAN | BAKER FELIX | Baker Brothers Life Sciences LP | Baker Bros. Advisors (GP) LLC | 667, L.P. | BAKER BROS. ADVISORS LP Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Non- Qualified Stock Option (right to buy)uy) Derivative · Indirect · See Footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $9.95 exercise price | 2024-03-14 | |
| 2024-03-01 | Keyt Bruce Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Stock Option (right to buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,026 0 owned after | $0.93 exercise price | 2024-03-05 |